Women with POI can be informed that there is no evidence that HT use increases their risk of breast cancer compared to women of the same age without POI.	CONDITIONAL ⊕⊕◯◯
HT is generally not recommended in women with a history of breast cancer.	STRONG ⊕⊕⊕◯
Women with BRCA1/2 mutations without a personal history of breast cancer should be advised that HT is an option after risk-reducing bilateral salpingo-oophorectomy.	STRONG ⊕⊕◯◯
A progestogen should be given in combination with estrogen therapy to all women with an intact uterus to prevent endometrial hyperplasia/cancer.	STRONG ⊕⊕◯◯
The guideline group recommends that the dose of progestogen is increased when higher doses of estrogen therapy are used.	GPP
The guideline group recommends that in women with POI, as with any women using HT, unscheduled bleeding requires assessment.	GPP
The guideline group recommends that women with POI and a history of endometriosis should be treated with combined estrogen–progestogen HT, even after hysterectomy, to avoid recurrence of endometriosis or malignant transformation.	GPP
Migraine should not be considered a contraindication to HRT use by women with POI.	STRONG ⊕⊕◯◯
HCPs should consider changing dose, route of administration, or regimen if migraine worsens during HRT.	STRONG ⊕⊕◯◯
Women with POI and migraine with aura should be advised to use transdermal estrogen as this may be the lowest-risk route of administration.	STRONG ⊕◯◯◯